BOGANI, COSTANZA
BOGANI, COSTANZA
Medicina Sperimentale e Clinica
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.
2007 Costanza Bogani; Paola Guglielmelli; Elisabetta Antonioli; Alessandro Pancrazzi; Alberto Bosi; Alessandro Maria Vannucchi
Breast cancer resistance protein (BCRP) expression and activity in mitochondria of different multiple drug-resistant (MDR) cancer cell lines
2009 Mazzanti, R; Solazzo, M; Fantappie, O; D'Amico, M; Sassoli, C; Tani, A; Cipriani, G; Bogani, C; Pestrin, M; Formigli, L
Caratterizzazione di alterazioni molecolari relative alla patogenesi delle Neoplasie Mieloproliferative Croniche
2009 C. Bogani
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.
2005 Antonioli E; Guglielmelli P; Pancrazzi A; Bogani C; Verrucci M; Ponziani V; Longo G; Bosi A; Vannucchi AM.
Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
2013 Bartalucci N;Tozzi L;Bogani C;Martinelli S;Rotunno G;Villeval JL;Vannucchi AM
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
2009 Vannucchi AM; Guglielmelli P; Rambaldi A; Bogani C; Barbui T.
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
2015 Pardanani, A; Tefferi, A; Guglielmelli, P; Bogani, C; Bartalucci, N; Rodríguez, J; Extremera, S; Pérez, I; Alfaro, V; Vannucchi, A M
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.
2008 Costanza Bogani; Vanessa Ponziani; Paola Guglielmelli; Cristophe Desterke; Vittorio Rosti; Alberto Bosi; Marie-Caroline Le Bousse-Kerdilès; Giovanni Barosi; Alessandro M Vannucchi.
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases
2006 Vannucchi, A.; Guglielmelli, P.; Antonioli, E.; Mappa, S.; Pancrazzi, A.; Bogani, C.; Ponziani, V.; Bosi, A.
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
2009 Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A.
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis
2015 Salati, Simona; Zini, Roberta; Nuzzo, Simona; Guglielmelli, Paola; Pennucci, Valentina; Prudente, Zelia; Ruberti, Samantha; Rontauroli, Sebastiano; Norfo, Ruggiero; Bianchi, Elisa; Bogani, Costanza; Rotunno, Giada; Fanelli, Tiziana; Mannarelli, Carmela; Rosti, Vittorio; Salmoiraghi, Silvia; Pietra, Daniela; Ferrari, Sergio; Barosi, Giovanni; Rambaldi, Alessandro; Cazzola, Mario; Bicciato, Silvio; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella
JAK PI3K/mTOR COMBINATION THERAPY
2013 Alessandro M. Vannucchi; Costanza Bogani; Niccolò Bartalucci
MicroRNA expression profile in granulocytes from primary myelofibrosis patients.
2007 Paola Guglielmelli; Lorenzo Tozzi; Alessandro Pancrazzi; Costanza Bogani; Elisabetta Antonioli; Vanessa Ponziani; Giada Poli; Roberta Zini; Sergio Ferrari; Rossella Manfredini; Alberto Bosi; Alessandro M Vannucchi.
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis.
2014 Norfo R;Zini R;Pennucci V;Bianchi E;Salati S;Guglielmelli P;Bogani C;Fanelli T;Mannarelli C;Rosti V;Pietra D;Salmoiraghi S;Bisognin A;Ruberti S;Rontauroli S;Sacchi G;Prudente Z;Barosi G;Cazzola M;Rambaldi A;Bortoluzzi S;Ferrari S;Tagliafico E;Vannucchi AM;Manfredini R
Mitochondrial expression and functional activity of Breast Cancer Resistance Protein in different multiple drug-resistant cell lines
2009 M. Solazzo; O. FANTAPPIE'; M. D'Amico; C. Sassoli; A. Tani; G. Cipriani; C. Bogani; L. Formigli; R. Mazzanti
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).
2007 Paola Guglielmelli; Roberta Zini; Costanza Bogani; Simona Salati; Alessandro Pancrazzi; Elisa Bianchi; Francesco Mannelli; Sergio Ferrari; Marie-Caroline Le Bousse-Kerdilès; Alberto Bosi; Giovanni Barosi; Anna Rita Migliaccio; Rossella Manfredini; Alessandro M Vannucchi
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
2013 Bogani C;Bartalucci N;Martinelli S;Tozzi L;Guglielmelli P;Bosi A;Vannucchi AM.
mTOR/JAK INHIBITOR COMBINATION THERAPY
2012 A.M. VANNUCCHI; C. BOGANI; P. GUGLIELMELLI; NOVARTIS PHARMA AG; INCYTE CORP.
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera.
2011 Guglielmelli, P.; Tozzi, L.; Bogani, C.; Iacobucci, I.; Ponziani, V.; Martinelli, G.; Bosi, A.; Vannucchi, A.M. .
Preclinical models for drug selection in myeloproliferative neoplasms.
2013 Bartalucci N;Bogani C;Vannucchi AM
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. | 2007 | Costanza Bogani; Paola Guglielmelli; Elisabetta Antonioli; Alessandro Pancrazzi; Alberto Bosi; Alessandro Maria Vannucchi | |
| Breast cancer resistance protein (BCRP) expression and activity in mitochondria of different multiple drug-resistant (MDR) cancer cell lines | 2009 | Mazzanti, R; Solazzo, M; Fantappie, O; D'Amico, M; Sassoli, C; Tani, A; Cipriani, G; Bogani, C; Pestrin, M; Formigli, L | |
| Caratterizzazione di alterazioni molecolari relative alla patogenesi delle Neoplasie Mieloproliferative Croniche | 2009 | C. Bogani | |
| Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. | 2005 | Antonioli E; Guglielmelli P; Pancrazzi A; Bogani C; Verrucci M; Ponziani V; Longo G; Bosi A; Vannucchi AM. | |
| Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. | 2013 | Bartalucci N;Tozzi L;Bogani C;Martinelli S;Rotunno G;Villeval JL;Vannucchi AM | |
| Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives | 2009 | Vannucchi AM; Guglielmelli P; Rambaldi A; Bogani C; Barbui T. | |
| Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial | 2015 | Pardanani, A; Tefferi, A; Guglielmelli, P; Bogani, C; Bartalucci, N; Rodríguez, J; Extremera, S; Pérez, I; Alfaro, V; Vannucchi, A M | |
| Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. | 2008 | Costanza Bogani; Vanessa Ponziani; Paola Guglielmelli; Cristophe Desterke; Vittorio Rosti; Alberto Bosi; Marie-Caroline Le Bousse-Kerdilès; Giovanni Barosi; Alessandro M Vannucchi. | |
| Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases | 2006 | Vannucchi, A.; Guglielmelli, P.; Antonioli, E.; Mappa, S.; Pancrazzi, A.; Bogani, C.; Ponziani, V.; Bosi, A. | |
| Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. | 2009 | Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A. | |
| Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis | 2015 | Salati, Simona; Zini, Roberta; Nuzzo, Simona; Guglielmelli, Paola; Pennucci, Valentina; Prudente, Zelia; Ruberti, Samantha; Rontauroli, Sebastiano; Norfo, Ruggiero; Bianchi, Elisa; Bogani, Costanza; Rotunno, Giada; Fanelli, Tiziana; Mannarelli, Carmela; Rosti, Vittorio; Salmoiraghi, Silvia; Pietra, Daniela; Ferrari, Sergio; Barosi, Giovanni; Rambaldi, Alessandro; Cazzola, Mario; Bicciato, Silvio; Tagliafico, Enrico; Vannucchi, Alessandro M; Manfredini, Rossella | |
| JAK PI3K/mTOR COMBINATION THERAPY | 2013 | Alessandro M. Vannucchi; Costanza Bogani; Niccolò Bartalucci | |
| MicroRNA expression profile in granulocytes from primary myelofibrosis patients. | 2007 | Paola Guglielmelli; Lorenzo Tozzi; Alessandro Pancrazzi; Costanza Bogani; Elisabetta Antonioli; Vanessa Ponziani; Giada Poli; Roberta Zini; Sergio Ferrari; Rossella Manfredini; Alberto Bosi; Alessandro M Vannucchi. | |
| miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis. | 2014 | Norfo R;Zini R;Pennucci V;Bianchi E;Salati S;Guglielmelli P;Bogani C;Fanelli T;Mannarelli C;Rosti V;Pietra D;Salmoiraghi S;Bisognin A;Ruberti S;Rontauroli S;Sacchi G;Prudente Z;Barosi G;Cazzola M;Rambaldi A;Bortoluzzi S;Ferrari S;Tagliafico E;Vannucchi AM;Manfredini R | |
| Mitochondrial expression and functional activity of Breast Cancer Resistance Protein in different multiple drug-resistant cell lines | 2009 | M. Solazzo; O. FANTAPPIE'; M. D'Amico; C. Sassoli; A. Tani; G. Cipriani; C. Bogani; L. Formigli; R. Mazzanti | |
| Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). | 2007 | Paola Guglielmelli; Roberta Zini; Costanza Bogani; Simona Salati; Alessandro Pancrazzi; Elisa Bianchi; Francesco Mannelli; Sergio Ferrari; Marie-Caroline Le Bousse-Kerdilès; Alberto Bosi; Giovanni Barosi; Anna Rita Migliaccio; Rossella Manfredini; Alessandro M Vannucchi | |
| mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. | 2013 | Bogani C;Bartalucci N;Martinelli S;Tozzi L;Guglielmelli P;Bosi A;Vannucchi AM. | |
| mTOR/JAK INHIBITOR COMBINATION THERAPY | 2012 | A.M. VANNUCCHI; C. BOGANI; P. GUGLIELMELLI; NOVARTIS PHARMA AG; INCYTE CORP. | |
| Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. | 2011 | Guglielmelli, P.; Tozzi, L.; Bogani, C.; Iacobucci, I.; Ponziani, V.; Martinelli, G.; Bosi, A.; Vannucchi, A.M. . | |
| Preclinical models for drug selection in myeloproliferative neoplasms. | 2013 | Bartalucci N;Bogani C;Vannucchi AM |